Apalife 10/Apalife 15

Apalife 10/Apalife 15 Dosage/Direction for Use

aripiprazole

Manufacturer:

Unison

Distributor:

Medispec
Full Prescribing Info
Dosage/Direction for Use
Schizophrenia: The recommended starting dose for Aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.
The maintenance dose for Aripiprazole is 15 mg/day. Doses in the range of 1- to 30 mg/day have been established as effective in clinical trials.
Bipolar Mania: Aripiprazole should be administered on a once-a-day schedule without regard to meals, generally starting a dose of 15 or 30 mg/day. Dose adjustments, if indicated, should occur at intervals of not less than 24 hours. Antimanic efficacy (3-12 weeks) was demonstrated in a dose range of 15 to 30 mg/day in clinical trials. The safety of doses above 30 mg/day has not been evaluated in clinical trials.
Patients taking medications metabolized by CYP2D6 of 3A4: Dosage adjustments for patients taking Aripiprazole concomitantly with potent CYP3A4 of CYP2D6 inhibitors: When concomitant administration of a potent CYP3A4 or CYP2D6 inhibitor with Aripiprazole occurs, the Aripiprazole dose should be reduced to one-half of the usual dose. When the CYP3A4 or CYP2D6 inhibitor is withdrawn from the combination therapy, the Aripiprazole dose should then be increased.
Dosage adjustments for patients taking potent CYP3A4 inducers: When a potent CYP3A4 inducers is added to Aripiprazole therapy, the Aripiprazole dose should be doubled. Additional dose increases of Aripiprazole should be based on clinical evaluation. When the CYP3A4 inducer is withdrawn from the combination therapy, the Aripiprazole dose should be reduced. Consideration should be given to reducing the daily dose in individual patients who are on multiple concomitant medications that inhibit CYP3A4 and CYP2D6 enzymes.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in